MH Guide 5.2 – Improved focus. Greater flexibility. Better usability.

MH Guide 5.2 – Improved focus. Greater flexibility. Better usability.

When it comes to targeted cancer treatments, new biomarkers are continually found, and additional treatment options are approved. Keeping pace with those changes with MH Guide 5.2.

Noteworthy updates include:

  • Regulatory agency information to focus on locally approved biomarkers
  • Multiple variants can be simultaneously managed with just a few clicks

Improved display of HRD and MSI scores

Read more

MH Guide Webinar – 28.04.2022 5:00 pm CET

MH Guide Webinar – 28.04.2022 5:00 pm CET

You’re invited to Molecular Health’s MH Guide webinar, a free-to-attend virtual event showcasing how to automatically identify clinically actionable biomarkers in molecular tumor profiles of individual patients. It uses an expert-curated knowledge base that enables fast and standardized interpretation and reporting workflows for NGS labs of any size and any throughput demand.

Join our Live Webinar on on April 28th, 2022, at 5:00 pm CET to find out how to use MH Guide to scale and automate your workflows. Click here to register.

Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions

Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions

Heidelberg, 10 March 2022 – Molecular Health and collaborators at the University of Florida College of Pharmacy, Takeda Oncology, and thinkQ2 published a triad of articles that describe and prove the concept of a novel systems approach to elucidate molecular mechanisms of drug toxicities using real-world data (RWD).

We have established an approach that transforms real-world, in-human treatment outcomes and safety data into extensive datasets to better characterize desirable and undesirable interactions between molecular pathways and drugs,” explains Dr. David Jackson, Chief Innovation Officer at Molecular Health and co-author on all three articles. “The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts.”

In an article published in CPT: Pharmacometrics & Systems Pharmacology, the research groups at Molecular Health and University of Florida discuss the principles and future potential of applying a reverse translational strategy in drug development to investigate drug effects at the molecular level, understand causality, and anticipate prevalence of adverse effects. They then demonstrate the approach in two subsequent articles authored with collaborators at Takeda Oncology and thinkQ2. By mapping population-level adverse drug reaction data extracted from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System back to molecular pathways and target profile data, the two proof-of-concept studies examined potential causes of cardiotoxicity and of colitis associated with well-known targeted cancer therapies. Using this analytical method, the authors developed hypotheses about different molecular mechanisms that accentuate or attenuate adverse effects depending on the nature of drug-drug combinations or on a drug’s target.

Dr. Mirjam Trame, Adjunct Professor at the University of Florida, principal investigator and corresponding author, Dr. Sarah Kim, Assistant Professor in the Department of Pharmaceutics, and Professor Emeritus Dr. Lawrence Lesko led the research collaboration. With nearly 20 years of experience directing Clinical Pharmacology at the U.S. FDA, Dr. Lesko is a renowned systems pharmacologist and Founding Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida in Lake Nona. He emphasizes the importance of this work: “Registries of adverse events constitute a diverse, massive and valuable data source that has not been tapped into to generate and assess molecular hypotheses about causality. The expansion of adverse event information coupled with biological and chemical data, as demonstrated in these studies, is an improvement over traditional pharmacovigilance and can inform future clinical trial designs and personalized medicine.”

Merging molecular knowledge with post-marketing adverse event reports to assess drug safety

The first proof-of-concept study, published in Clinical and Translational Science (CTS), analyzed mechanistic hypotheses in light of cardiotoxicity reports from patients on trastuzumab (HerceptinR) combined with one of four other medications. A monoclonal antibody, trastuzumab targets HER2 and is used to treat breast cancer and advanced stomach cancer. Corroborated with experimental findings in the literature, the study suggested that trastuzumab-induced cardiotoxicity may be enhanced by doxorubicin via mitochondria dysfunction in cardiomyocytes, whereas the combination with tamoxifen, paroxetine, or lapatinib may diminish the undesirable effect by increasing antioxidant activities.

The second proof-of-concept study, published in CTS: Clinical and Translational Science, investigated autoimmunity associated with immunotherapies. The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab are used for a broad range of cancers and treatment is often accompanied by severe colitis. Results of this study revealed that differences in mode of action – ipilimumab inhibits CTLA-4 whereas nivolumab and pembrolizumab target PD-1 – accounted for a three-fold higher reporting rate of colitis linked to ipilimumab. Mapping chemical and biological data to adverse events reports suggested that ipilimumab may unblock the immune response earlier, leading to heightened T-cell activation.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions leverage the transformation of large amounts of data into evidence-based, medically relevant decision support to benefit patients, healthcare providers, and drug developers. At Molecular Health, specialists in medicine, data science, biology, bioinformatics, and software development work to maintain and advance clinical decision support platforms that enable physicians to make better personalized treatment decisions. Exploiting its proprietary database Dataome with the power of AI analyses supervised by unbiased experts, Molecular Health enables innovative and value-adding decision making in the discovery and development of precision medicine. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

Download pdf

Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Heidelberg, 19. October 2021 – Molecular Health and the life science company Gen Era Diagnostics have signed a collaboration agreement to optimize the personalized treatment of patients with cancer. For this purpose, Gen Era will provide the MH Guide software platform to twenty laboratories in Turkey to use in the interpretation of tumor data.

“We are pleased to have Molecular Health on board in the near future as an experienced partner in precision medicine. With MH Guide, we can analyze and interpret molecular genetic data even faster and more comprehensively. This is an important addition to our service and product portfolio,” explains Damla Bozkulak, Head of Marketing and Business Development at Gen Era Diagnostics.

Gen Era Diagnostics is one of the leading product and service providers in the field of molecular diagnostics in Turkey. Founded in 2013, the company supports scientists, clinicians, and laboratories in the investigation of diseases and the treatment of patients. Gen Era’s offering includes solutions and services for molecular diagnostics in the fields of oncology, cardiology, and metabolic diseases, among others. In addition, the company offers services for the life sciences, including genomics, proteomics, and cell analyses.

“With MH Guide, doctors can manage the flood of data from molecular genetic testing and translate it into targeted therapy recommendations. We value the trust that Gen Era Diagnostics has placed in our technology and are convinced that patients in Turkey will benefit from it,” explains Thomas Holtrup, Senior Vice President, Head of Sales & Business Development, EMEA, at Molecular Health.

MH Guide is an analysis software for interpreting molecular data from cancer patients. It summarizes in a report the relevant genetic changes of a tumor that can be specifically addressed in individual patients either therapeutically or in clinical trials. In this way, treatment options can be expanded, especially for patients with metastatic disease.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About Gen Era Diagnostics:

Gen Era Diagnostics is a biotech company founded in 2013. It is one of the leading institutions in the fields of molecular diagnostics and life science research in Turkey. With its service and product portfolio, Gen Era Diagnostics supports scientists, clinics and laboratories in the research, diagnosis and treatment of diseases. This includes oncological indications, cardiology, hematology and rare genetic diseases. In addition, Gen Era supports research projects in the fields of genomics, proteomics and cell analysis and offers bioinformatics services for scientific institutions.

More information at  Gen Era Diagnostik

Download pdf

The potential of liquid biopsies for early cancer detection powered by ONCOCATCH and MH Guide

The potential of liquid biopsies for early cancer detection powered by ONCOCATCH and MH Guide

Molecular Health will join partner EONE-Diagnomics Genome Center (EDGC) in the EDGC seminar “Liquid biopsy for early detection of multiple cancers and Molecular Health GmbH introduction” on Wednesday, 13 October at 16:00–17:00 Korean Standard Time (GMT+9).

An international joint venture between EONE Laboratories and Diagnomics, EDGC develops novel genome analysis technologies to advance diagnostic capabilities in a broad range of diseases and over the lifetime of a patient. Their advanced tools in precision and personalized medicine include ONCOCATCH, an IVD service for cancer detection based on the analysis of circulating tumor DNA in liquid biopsies.

MH Guide from Molecular Health is an EU-registered IVD software that supports treatment decisions via expert annotation and interpretation of genomic data, including the analysis of liquid biopsies. By evaluating genomic data in the context of a comprehensive biomedical information landscape, MH Guide delivers up-to-date and easy-to-use information on clinically relevant biomarkers and clinical trials.

The joint seminar will discuss the unique advantages of coupling ONCOCATCH and MH Guide to evaluate cancer variants in blood for timely, evidence-based treatment decisions. Please join us for this informative presentation.

https://forms.gle/Yh79n1tYJHmkWRXn8

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

Heidelberg, September 30, 2021. Molecular Health has launched the latest version of its analysis software MH Guide. This software, which is used by pathology laboratories and molecular tumor boards, now has improved search capabilities to identify patient- relevant clinical studies. With the VCF Adapter Suite, Molecular Health also offers a conversion tool to easily integrate data from the most common NGS sequencing systems.

The current version of MH Guide contains an optimized search and filter function for identifying relevant clinical studies. This allows more cancer patients to access studies that are suitable for them.

The VCF Adapter Suite was introduced alongside MH Guide 5.0. This conversion tool enables a simple connection to common NGS analysis systems. Currently, the following data can be converted into an MH Guide-compatible format:

• Illumina (TSO500, TST170, AmpliSeq)
• ArcherDX
• Qiagen
• Thermo Fisher Oncomine
• AmoyDx

This facilitates individual conversions and supports integration into fully automated processes.

“Many molecular pathology laboratories are now using our software for patients, who can benefit from targeted therapy or participation in a clinical trial based on the comprehensive analysis of their tumor genome,” explains PD Dr. Christian Meisel, Chief Medical Officer of Molecular Health. “This means that the treatment spectrum can be expanded and affected people can be given options,” Meisel continues.

“We are continuously working on improvements to our software and will continue to accommodate the use requirements of molecular tumor boards in further updates of MH Guide. Our goal is to provide the best possible information for evidence-based therapy decisions at all times,” explains Dr. Matthias Kopf, Head of Product Management at Molecular Health.

MH Guide is a browser-based software that is used in therapy planning for cancer patients. The software enables the automatic analysis of molecular data obtained using Next Generation Sequencing (NGS), and provides treating physicians with an evidence-based report for personalized therapy approaches. This report contains information on potentially effective targeted and immuno-oncological therapies and on ongoing clinical studies for which the patient is eligible. With the current software update (MH Guide 5.0), Molecular Health has made an improved version of the application available since September 1, 2021.

MH Guide is a proprietary technology from Molecular Health, an internationally active biotech IT company in Heidelberg, Germany. The software compares sequence data from molecular testing with information from one of the world’s largest and growing knowledge platforms (Dataome). Thus, the tool enables molecular pathologists and practitioners to keep pace with rapidly expanding medical knowledge and use insights for the treatment of their patients. 

Users can access the current version of MH Guide via https://analysis.mh.guide. Interested parties can obtain further information on the customerservice@molecularhealth.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

Download pdf

What’s new in MH Guide version 5.0

Discover what’s new in MH Guide version 5.0

As of September 1, 2021, version 5.0 of MH Guide is available. The improved solution offers numerous updates and new features, including:

  • Flexible customizations of the MH Guide report, including custom input fields
  • Optimized search and filter tools to better identify relevant clinical trials and
    highlight these in MH Guide reports
  • The MH VCF Adapter Suite to easy convert variant data into an MH-compatible VCF format

Learn in detail how MH Guide 5.0 accelerates insights.
Please download PDF here.

Molecular Health and Korean EONE-Diagnomics Genome Center (EDGC) join forces in liquid biopsy-based precision medicine

Heidelberg/Incheon, 15. September 2021. Molecular Health GmbH will collaborate with EONE-Diagnomics Genome Center Co. Ltd. (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients. The collaboration is intended to establish leadership in the fast-growing precision medicine market for liquid biopsy. Therefore, the two partners combine two major proprietary technologies, Molecular Health’s MH Guide and EDGC’s ONCOCATCH-CDxTM. This allows comprehensive genomic tumor profiling to guide treatment in solid tumors.

“The cooperation between Molecular Health and EDGC connects two well-established players in the field of precision medicine and forms an alliance that has the potential to significantly improve diagnosis and tailored treatment of cancer patients”, says Stephan Hettich, SVP, Head of Sales & Business Development, APAC with Molecular Health. “We are very happy to have found a strong and experienced partner like EDGC to capture the Asian market together.”

EDGC is an international joint venture based in South Korea that develops leading-edge technology for genome analysis and precision as well as personalized medicine. With ONCOCATCH-CDx the research and development company developed a unique non-invasive biopsy for early diagnosis, companion diagnostics and monitoring of all-stage cancer. The test analyses circulating tumor DNA (ctDNA), which is released from cancer cells into the bloodstream, through next-generation sequencing technology and state-of-the-art in-house bioinformatics. This provides the basis for personalized medicine prescription and helps doctors and patients in the decision-making. The global life science journal GenomeWeb labeled ONCOCATCH as ‘one of the world’s best-advanced technologies for early cancer diagnosis.

As part of the cooperation, EDGC aims to utilize Molecular Health’s MH Guide, analysis software that supports oncologists and molecular pathologists in the interpretation of large molecular datasets. Independent of the sequencing technology used, MH Guide can make complex datasets readable, and automatically identify genetic variants that are relevant for the treatment of cancer patients.

“When combining MH Guide, including 28.000 gene variant – drug relations, with EDGC’s companion diagnostics service ONCOCATCH-CDx, qualitative comprehensive genomic profiling results can be provided to guide treatment in solid tumors,” Jeong Yoo-seok, EDGC Global Business Department Team Leader, summarizes the collaboration. “We are looking forward to our partnership with Molecular Health to further establish our leading positions in the upcoming precision medicine market for liquid biopsy”, he adds.

Please note
On 13th October 2021, EGDC and Molecular Health will be hosting a joint a webinar to give further details on the collaboration and the future joint activities. Partners may register by contacting yubinakim@edgc.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

Kim Seung-Gyun
EONE-Diagnomics Genome Center
seongyun.kim@edgc.com
Tel.: +82 32713-2190

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About EONE-Diagnomics Genome Center:

EDGC is the international joint venture established in 2013 between EONE Laboratories and Diagnomics. EDGC has developed leading-edge technology for genome analysis through constant research and development and has established a business network to expand its influence on the global market. Because of that, EDGC diagnoses various diseases over the entire life cycle and provides clinical solution for precision and personalized medicine. As the global leader of genome business, EDGC has worked on global projects with the most influential BT and IT companies in the world such as Illumina and Microsoft.

Read more on www.edgc.com

Download pdf